<!-- SPDX-License-Identifier: PolyForm-Noncommercial-1.0.0 -->

---
title: "Expanding Treatment Opportunities: Injectable Antiretrovirals for HIV"
date: 2025-12-24
authors:
  - AI Whisperers
version: "0.1"
license: PolyForm-Noncommercial-1.0.0
---

# Expanding Treatment Opportunities: Injectable Antiretrovirals for HIV

**ID:** TRT-011
**Year:** 2024
**Journal:** Infectious Diseases and Therapy
**DOI:** [10.1007/s40121-024-01062-6](https://link.springer.com/article/10.1007/s40121-024-01062-6)
**PMC:** [PMC11582110](https://pmc.ncbi.nlm.nih.gov/articles/PMC11582110/)
**PubMed:** [39417932](https://pubmed.ncbi.nlm.nih.gov/39417932/)

---

## Abstract

This comprehensive 2024 review examines the current landscape of injectable antiretrovirals for HIV treatment, including FDA-approved options (cabotegravir/rilpivirine, lenacapavir, ibalizumab) and investigational agents. Long-acting injectables represent a paradigm shift from daily oral therapy, offering improved adherence, reduced stigma, and enhanced quality of life.

---

## Key Concepts

- **Long-Acting Injectables (LA-ART)**: Extended-release antiretroviral formulations
- **Cabenuva (CAB/RPV)**: First FDA-approved monthly injectable (2021)
- **Lenacapavir**: Twice-yearly capsid inhibitor
- **Ibalizumab**: Monthly monoclonal antibody infusion

---

## FDA-Approved Injectable Antiretrovirals

### Timeline
| Year | Drug | Indication |
|:-----|:-----|:-----------|
| 2018 | Ibalizumab | Treatment-experienced, MDR |
| 2021 | Cabotegravir/Rilpivirine | Maintenance therapy |
| 2022 | Lenacapavir (treatment) | Treatment-experienced |
| 2024 | Cabotegravir LA (PrEP) | HIV prevention |
| 2025 | Lenacapavir (PrEP) | HIV prevention |

> "In January 2021, the first injectable antiretroviral, cabotegravir/rilpivirine (CAB/RPV), was FDA approved for treatment of HIV."

---

## Lenacapavir

### Mechanism and Dosing
| Feature | Details |
|:--------|:--------|
| Drug class | First-in-class capsid inhibitor |
| Target | HIV-1 capsid protein (p24) |
| Route | Subcutaneous injection |
| Frequency | **Every 6 months** |

### Clinical Efficacy
| Trial | Population | Efficacy |
|:------|:-----------|:---------|
| CAPELLA | Treatment-experienced | High efficacy |
| PURPOSE 1 | Cisgender women (PrEP) | **100% efficacy** |
| PURPOSE 2 | MSM/trans (PrEP) | **96% reduction** |

> "According to Science magazine, which elected lenacapavir as 'Scientific Advance of the Year 2024'."

---

## Cabotegravir/Rilpivirine (Cabenuva)

### Regimen Details
| Feature | Details |
|:--------|:--------|
| Components | CAB (INSTI) + RPV (NNRTI) |
| Dosing | Monthly or every 2 months |
| Route | Intramuscular gluteal |
| Requirement | Virally suppressed on oral ART first |

---

## Combination LA-ART: Lenacapavir + Cabotegravir

### Case Series Data
| Parameter | Result |
|:----------|:-------|
| Patients on LEN/CAB | 34 |
| Virologic suppression | **94%** |
| Target price (Africa) | ~$80/year |

---

## Access and Equity

| Issue | Details |
|:------|:--------|
| Lenacapavir licensing | 120 low/middle-income countries |
| Latin America exclusion | Most countries not included |
| Supply chain | Cold chain requirements |

---

## Relevance to Project

Injectable antiretroviral research informs the Ternary VAE project:
- **Capsid sequences**: Lenacapavir binding site conservation
- **Resistance mutations**: Long-acting drug escape pathways
- **Drug target modeling**: Capsid and integrase structures

---

*Added: 2025-12-24*
